+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Low cocaine- and amphetamine-regulated transcript (CART) peptide levels in human cerebrospinal fluid of major depressive disorder (MDD) patients



Low cocaine- and amphetamine-regulated transcript (CART) peptide levels in human cerebrospinal fluid of major depressive disorder (MDD) patients



Journal of Affective Disorders 232: 134-138



Cocaine- and amphetamine-regulated transcript (CART) peptide is a candidate neuropeptide as a biomarker for major depressive disorder (MDD) because of its effects on emotion and distribution covering brain areas involved in the pathophysiology of MDD symptoms. However, it is unknown whether CART peptide levels are altered in the cerebrospinal fluid (CSF) of patients with MDD patients and are correlated with MDD symptoms. Subjects were 24 patients with MDD and 25 healthy controls matched for age, gender and ethnicity (Japanese). We measured CSF CART levels by a commercially available immunoassay kit and analyzed the relationships of the levels with antidepressant dose and symptoms assessed with the 21 item Hamilton Depression Rating Scale (HAMD-21). CSF CART levels were significantly decreased in the patients than in the controls (p < 0.05). In MDD patient group, the CART levels had a negative correlation with antidepressant dose (imipramine-equivalent dose) (ρ = -0.55, p < 0.01) and significantly decreased in antidepressant-treated group (AD-treated group) compared to controls (p < 0.05). CSF CART levels showed significant negative correlations with psychomotor retardation, somatic anxiety, and general somatic symptoms (all p < 0.05) and a positive correlation with obsessive and compulsive symptoms (p < 0.05). In our analysis, all classes of antidepressants were combined together and the effects of medication use in a longitudinal manner did not confirm. We report for the first time that CSF CART peptide levels are reduced in patients with MDD compared with healthy controls. The CART levels showed negative correlations with antidepressant dose and some symptoms, supporting the possibility that CART peptide is involved in the development of depressive symptoms.

(PDF emailed within 0-6 h: $19.90)

Accession: 065289904

Download citation: RISBibTeXText

PMID: 29486339

DOI: 10.1016/j.jad.2018.02.039


Related references

Cocaine and amphetamine-regulated transcript peptide (CART(62-76))-induced changes in regional monoamine levels in ratbrain. Neuropeptides 35(5-6): 292-296, 2002

CART (cocaine- and amphetamine-regulated transcript) peptide specific binding sites in PC12 cells have characteristics of CART peptide receptors. Brain Research 1547: 16-24, 2014

Injection of Cocaine-Amphetamine Regulated Transcript (CART) peptide into the nucleus accumbens does not inhibit caffeine-induced locomotor activity: Implications for CART peptide mechanism. Pharmacology, Biochemistry, and Behavior 148: 8-14, 2017

Orexin A (hypocretin-1) levels are not reduced while cocaine/amphetamine regulated transcript levels are increased in the cerebrospinal fluid of patients with multiple sclerosis: no correlation with fatigue and sleepiness. Journal of the Neurological Sciences 307(1-2): 127-131, 2012

Injection of CART (cocaine- and amphetamine-regulated transcript) peptide into the nucleus accumbens reduces cocaine self-administration in rats. Behavioural Brain Research 191(2): 266-271, 2008

Intra-accumbal injection of CART (cocaine-amphetamine regulated transcript) peptide reduces cocaine-induced locomotor activity. Journal of Pharmacology and Experimental Therapeutics 307(3): 1038-1044, 2003

In vivo cerebrovascular effects of cocaine- and amphetamine-regulated transcript (CART) peptide. Journal of Cardiovascular Pharmacology 52(1): 82-89, 2008

Cocaine-and-Amphetamine Regulated Transcript (CART) peptide attenuates dopamine- and cocaine-mediated locomotor activity in both male and female rats: lack of sex differences. Neuropeptides 48(2): 75-81, 2014

Microinjection of CART (cocaine- and amphetamine-regulated transcript) peptide into the nucleus accumbens inhibits the cocaine-induced upregulation of dopamine receptors and locomotor sensitization. Neurochemistry International 75: 105-111, 2015

Cocaine- and amphetamine-regulated transcript (CART) peptide: a vasoactive role in the cerebral circulation. Journal of Cerebral Blood Flow and Metabolism 25(10): 1376-1385, 2005

Structure-activity relationship of CART (cocaine- and amphetamine-regulated transcript) peptide fragments. Peptides 28(10): 1945-1953, 2007

Multiple behavioral effects of cocaine- and amphetamine-regulated transcript (CART) peptides in mice: CART 42-89 and CART 49-89 differ in potency and activity. Journal of Pharmacology and Experimental Therapeutics 299(3): 1021-1026, 2001

Involvement of the cocaine-amphetamine regulated transcript peptide (CART 55-102) in the modulation of rat immune cell activity. Neuro Endocrinology Letters 29(3): 359-365, 2008

Localisation and morphology of cocaine- and amphetamine-regulated transcript (CART) peptide immunoreactive neurons in rat amygdala. Acta Veterinaria 55(5-6): 423-434, 2005

CART (cocaine- and amphetamine-regulated transcript) peptide receptors: specific binding in AtT20 cells. European Journal of Pharmacology 528(1-3): 188-189, 2005